Quotient Acquires Charles River’s CDMO Unit


From DCAT Value Chain Insights (VCI)

By Supplier News posted 02-18-2017 01:47

  

Quotient Clinical, a Nottingham, UK-based early phase drug development services provider, has acquired QS Pharma, Charles River Laboratories International’s contract development and manufacturing organization unit based near Philadelphia.

Founded in 2002, QS Pharma specializes in the formulation development and manufacturing of small-molecule drug products and from  development  to commercialization. Quotient gains QS Pharma’s capability in high-potency manufacturing.

This acquisition expands Quotient’s footprint in the US following its recent acquisition of SeaView Research, a Miami, Florida-based clinical research organization, this month. The two acquisitions boost Quotient’s capability to replicate its proprietary Translational Pharmaceutics technology platform in the US, which integrates clinical testing with formulation development and GMP manufacturing.

Source: Quotient Clinical 

0 comments
67 views


Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT). 

Learn more and sign up to receive a complimentary subscription 

Permalink

Tag

Comments